1
|
Toupet K, Jorgensen C, Noël D. An injectable copolymer of fatty acids (ARA 3000 BETA) as a promising treatment for osteoarthritis. Sci Rep 2023; 13:7783. [PMID: 37179423 PMCID: PMC10183038 DOI: 10.1038/s41598-023-34206-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2023] [Accepted: 04/26/2023] [Indexed: 05/15/2023] Open
Abstract
Osteoarthritis (OA) is the most prevalent rheumatic disease and a fast growing cause of disability. Current pharmacological treatments include antalgics and non-steroid anti-inflammatory drugs to control pain and inflammation as well as slow acting drugs such as intra-articular (IA) administration of hyaluronic acid. Oral supplementation or diet rich in polyunsaturated free fatty acids are proposed but evidence for benefit is still under debate. We here investigated the therapeutic potential of ARA 3000 BETA, an injectable copolymer of fatty acids, at the structural level in OA. Collagenase-induced osteoarthritis model was induced in C57BL/6 mice by collagenase injection into knee joint. Mice were treated with one or two IA or four intra-muscular injections (IM) of ARA 3000 BETA. At sacrifice, knee joints were recovered for cartilage analysis by confocal laser scanning microscopy (CLSM) and bone analysis by micro-computed tomography system. OA histological scoring was performed after safranin O/fast green staining. Histological analysis revealed a protective effect against cartilage degradation in treated knee joints after IM and IA administration. This was confirmed by CLSM with a significant improvement of all articular cartilage parameters, including thickness, volume and surface degradation whatever the administration route. A slight protective effect was also noticed on subchondral bone parameters and knee joint calcification after IM administration and to a lesser extent, two IA injections. We demonstrated the therapeutic efficacy of injectable ARA 3000 BETA in OA with a protection against cartilage and bone alterations providing the proof-of-concept that clinical translation might be envisioned to delay disease progression.
Collapse
Affiliation(s)
- Karine Toupet
- IRMB, University of Montpellier, INSERM, Montpellier, France
- ECELLFRANCE, University of Montpellier, INSERM, CHU Montpellier, Montpellier, France
| | - Christian Jorgensen
- IRMB, University of Montpellier, INSERM, Montpellier, France
- ECELLFRANCE, University of Montpellier, INSERM, CHU Montpellier, Montpellier, France
- Clinical Immunology and Osteoarticular Diseases Therapeutic Unit, Hôpital Lapeyronie, Montpellier, France
| | - Danièle Noël
- IRMB, University of Montpellier, INSERM, Montpellier, France.
- ECELLFRANCE, University of Montpellier, INSERM, CHU Montpellier, Montpellier, France.
- Clinical Immunology and Osteoarticular Diseases Therapeutic Unit, Hôpital Lapeyronie, Montpellier, France.
| |
Collapse
|
2
|
Plasma Fatty Acids Pattern and Dry Eye Disease in the Elderly: The Montrachet Population-Based Study. Nutrients 2022; 14:nu14112290. [PMID: 35684090 PMCID: PMC9183164 DOI: 10.3390/nu14112290] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2022] [Revised: 05/19/2022] [Accepted: 05/25/2022] [Indexed: 11/16/2022] Open
Abstract
(1) Background: To investigate the association between plasma fatty acids (FAs) and dry eye disease (DED) in an elderly population; (2) Methods: We conducted a population-based study, the Montrachet study, in individuals older than 75 years. DED was evaluated using the Schirmer I test without anesthesia, tear film breakup time (TFBUT) measurement and fluorescein corneal staining. Plasma FAs were measured in fasting blood using gas chromatography; (3) Results: A total of 740 subjects with a plasma measurement of 25 FAs were included in this study. The mean age was 82.2 ± 3.7 years, and 62.7% were women. DED was present in 35.0% of participants. We identified a plasma FAs pattern positively associated with DED, characterized by low polyunsaturated fatty acids (PUFAs), high monounsaturated fatty acids (MUFAs) and low saturated fatty acids (SFAs) levels. After adjustment for major confounders, individuals in the upper quartile of the FAs pattern scores compared with those in the lower quartile were more likely to present DED (OR 2.46 (95% CI 1.51-4.01), p = 0.001); (4) Conclusion: In this study, we found that a plasma FAs pattern characterized by low PUFAs, high MUFAs and low SFAs was significantly associated with DED in elderly participants.
Collapse
|
3
|
Allas L, Brochard S, Rochoux Q, Ribet J, Dujarrier C, Veyssiere A, Aury-Landas J, Grard O, Leclercq S, Vivien D, Ea HK, Maubert E, Cohen-Solal M, Boumediene K, Agin V, Baugé C. EZH2 inhibition reduces cartilage loss and functional impairment related to osteoarthritis. Sci Rep 2020; 10:19577. [PMID: 33177650 PMCID: PMC7658239 DOI: 10.1038/s41598-020-76724-9] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2020] [Accepted: 10/29/2020] [Indexed: 12/19/2022] Open
Abstract
Histone methyltransferase EZH2 is upregulated during osteoarthritis (OA), which is the most widespread rheumatic disease worldwide, and a leading cause of disability. This study aimed to assess the impact of EZH2 inhibition on cartilage degradation, inflammation and functional disability. In vitro, gain and loss of EZH2 function were performed in human articular OA chondrocytes stimulated with IL-1β. In vivo, the effects of EZH2 inhibition were investigated on medial meniscectomy (MMX) OA mouse model. The tissue alterations were assayed by histology and the functional disabilities of the mice by actimetry and running wheel. In vitro, EZH2 overexpression exacerbated the action of IL-1β in chondrocytes increasing the expression of genes involved in inflammation, pain (NO, PGE2, IL6, NGF) and catabolism (MMPs), whereas EZH2 inhibition by a pharmacological inhibitor, EPZ-6438, reduced IL-1β effects. Ex vivo, EZH2 inhibition decreased IL-1β-induced degradation of cartilage. In vivo, intra-articular injections of the EZH2 inhibitor reduced cartilage degradation and improved motor functions of OA mice. This study demonstrates that the pharmacological inhibition of the histone methyl-transferase EZH2 slows the progression of osteoarthritis and improves motor functions in an experimental OA model, suggesting that EZH2 could be an effective target for the treatment of OA by reducing catabolism, inflammation and pain.
Collapse
Affiliation(s)
- Lyess Allas
- EA7451 BioConnect, Normandie Univ, Université de Caen, 14032, Caen, France
| | - Sybille Brochard
- EA7451 BioConnect, Normandie Univ, Université de Caen, 14032, Caen, France
| | - Quitterie Rochoux
- EA7451 BioConnect, Normandie Univ, Université de Caen, 14032, Caen, France
- Service de Rhumatologie, CHU, Caen, France
| | - Jules Ribet
- EA7451 BioConnect, Normandie Univ, Université de Caen, 14032, Caen, France
- Service de Rhumatologie, CHU, Caen, France
| | - Cleo Dujarrier
- UMRS1237 PhIND, INSERM, Normandie Univ, Institut Blood and Brain @ Caen-Normandie, Université de Caen, Caen, France
| | - Alexis Veyssiere
- EA7451 BioConnect, Normandie Univ, Université de Caen, 14032, Caen, France
- Service de Chirurgie Maxillo-Faciale, CHU, Caen, France
| | | | - Ophélie Grard
- EA7451 BioConnect, Normandie Univ, Université de Caen, 14032, Caen, France
| | - Sylvain Leclercq
- EA7451 BioConnect, Normandie Univ, Université de Caen, 14032, Caen, France
- Service de Chirurgie Orthopédique, Clinique Saint-Martin, Caen, France
| | - Denis Vivien
- UMRS1237 PhIND, INSERM, Normandie Univ, Institut Blood and Brain @ Caen-Normandie, Université de Caen, Caen, France
- Department of Clinical Research, CHU Caen-Normandie, Caen, France
| | - Hang-Korng Ea
- UMR-1132 BIOSCAR, INSERM, Université de Paris, Paris, France
| | - Eric Maubert
- UMRS1237 PhIND, INSERM, Normandie Univ, Institut Blood and Brain @ Caen-Normandie, Université de Caen, Caen, France
| | | | - Karim Boumediene
- EA7451 BioConnect, Normandie Univ, Université de Caen, 14032, Caen, France
| | - Véronique Agin
- UMRS1237 PhIND, INSERM, Normandie Univ, Institut Blood and Brain @ Caen-Normandie, Université de Caen, Caen, France
| | - Catherine Baugé
- EA7451 BioConnect, Normandie Univ, Université de Caen, 14032, Caen, France.
| |
Collapse
|
4
|
Allas L, Rochoux Q, Leclercq S, Boumédiene K, Baugé C. Development of a simple osteoarthritis model useful to predict in vitro the anti-hypertrophic action of drugs. J Transl Med 2020; 100:64-71. [PMID: 31409892 DOI: 10.1038/s41374-019-0303-0] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2019] [Revised: 06/18/2019] [Accepted: 07/07/2019] [Indexed: 12/13/2022] Open
Abstract
Osteoarthritis (OA) is characterized by cartilage degradation, inflammation, and hypertrophy. Therapies are mainly symptomatic and aim to manage pain. Consequently, medical community is waiting for new treatments able to reduce OA process. This study aims to develop an in vitro simple OA model useful to predict drug ability to reduce cartilage hypertrophy. Human primary OA chondrocytes were incubated with transforming growth factor beta 1 (TGF-β1). Hypertrophy was evaluated by Runx2, type X collagen, MMP13, and VEGF expression. Cartilage anabolism was investigated by Sox9, aggrecan, type II collagen, and glycosaminoglycan expression. In chondrocytes, TGF-β1 increased expression of hypertrophic genes and activated canonical WNT pathway, while it decreased dramatically cartilage anabolism, suggesting that this treatment could mimic some OA features in vitro. Additionally, EZH2 inhibition, that has been previously reported to decrease cartilage hypertrophy and reduce OA development in vivo, attenuated COL10A1 and MMP13 upregulation and SOX9 downregulation induced by TGF-β1 treatment. Similarly, pterosin B (an inhibitor of Sik3), and DMOG (a hypoxia-inducible factor prolyl hydroxylase which mimicks hypoxia), repressed the expression of hypertrophy markers in TGF-β stimulated chondrocytes. In conclusion, we established an innovative OA model in vitro. This cheap and simple model will be useful to quickly screen new drugs with potential anti-arthritic effects, in complementary to current inflammatory models, and should permit to accelerate development of efficient treatments against OA able to reduce cartilage hypertrophy.
Collapse
Affiliation(s)
- Lyess Allas
- Normandie Université, UNICAEN, EA7451, BioConnecT, Caen, France
| | - Quitterie Rochoux
- Normandie Université, UNICAEN, EA7451, BioConnecT, Caen, France.,CHU, Service de Rhumatologie, Caen, France
| | - Sylvain Leclercq
- Normandie Université, UNICAEN, EA7451, BioConnecT, Caen, France.,Clinique Saint-Martin, Service de Chirurgie Orthopédique, Caen, France
| | | | - Catherine Baugé
- Normandie Université, UNICAEN, EA7451, BioConnecT, Caen, France.
| |
Collapse
|
5
|
Baugé C, Leclercq S, Conrozier T, Boumediene K. TOL19-001 reduces inflammation and MMP expression in monolayer cultures of tendon cells. BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE 2015; 15:217. [PMID: 26156631 PMCID: PMC4495633 DOI: 10.1186/s12906-015-0748-7] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/12/2014] [Accepted: 06/25/2015] [Indexed: 12/16/2022]
Abstract
Background Tendinopathies are tendon conditions associated with degeneration and disorganization of the matrix collagen fibers, tendon cells apoptosis and inflammation through up-regulation of proinflammatory cytokines, matrix metalloproteinase (MMP) expression, and prostaglandin E2 (PGE2) production. Currently, the pharmacological treatment is mainly based on non-steroidal anti-inflammatory drugs (NSAIDs) use and corticosteroid injections, which both can lead to numerous side effects for patients. TOL19-001 is a diet supplementary composed mostly of spirulina and glucosamine sulfate whose antioxidant properties could be helpful to treat tendinopathies while avoiding taking NSAIDs. In this study we developed an in vitro model of tendinopathy in order to evaluate the therapeutic potential of TOL19-001. Methods Tendon cells were cultured on monolayer and treated with interleukin-1β (IL-1β) or ciprofloxacin (CIP), and then, MMPs, PGE2 and collagen expression was evaluated by RT-PCR or Elisa. In addition, a cotreatment with increased doses of TOL19-001 was done. Toxicity of TOL19-001 was evaluated using a metabolic activity assay. Results This study demonstrates that IL-1β mimics some aspects of tendinopathies with PGE2 induction, MMP expression (mostly MMP1 and MMP3), and increases of type III/I collagen ratio. CIP, meanwhile, leads to an increase of MMP2 and p65 mRNA, whereas it reduces TIMP1 expression. Scleraxis expression was also increased by CIP whereas it was decreased by IL-1β treatment. Besides, TOL19-001 cotreatment suppresses tendon cell inflammation in vitro, marked by the downregulation of PGE2, MMPs and type III collagen in IL-1β stimulated-cells. TOL19-001 also represses CIP induced-changes. Conclusions These findings indicate that TOL19-001 exerts anti-inflammatory effects on tendon cells, which might explain why TOL19-001 diet may improve tendon function in patients with tendon injury. Future research is required to determine TOL19-001 effect on injured or overused tendons in vivo.
Collapse
|